ストックスクリーナーアプリを入手
0.7785
3.99%
0.0299
前日終値:
$0.7486
開ける：
$0.75
24時間の取引高:
44,946
Relative Volume:
0.22
時価総額：
$42.44M
収益：
$76.19M
当期純損益:
$-1.61M
株価収益率:
77.85
EPS:
0.01
ネットキャッシュフロー:
$28.98M
1週間 パフォーマンス:
-1.21%
1か月 パフォーマンス:
-4.68%
6か月 パフォーマンス:
-43.18%
1年 パフォーマンス:
-53.10%
1日の値動き範囲:
$0.75
$0.7785
1週間の範囲:
$0.73
$0.80
52週間の値動き範囲:
$0.73
$1.89
Spero Therapeutics Inc Stock (SPRO) Company Profile
名前
Spero Therapeutics Inc
セクター
電話
857-242-1600
住所
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
SPRO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
0.7785 | 42.44M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-23 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-10-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-09-29 | 開始されました | Evercore ISI | Outperform |
| 2019-11-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-09-09 | 開始されました | Janney | Buy |
| 2018-02-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 開始されました | BofA/Merrill | Neutral |
| 2017-11-27 | 開始されました | Oppenheimer | Outperform |
| 2017-11-27 | 開始されました | Stifel | Buy |
すべてを表示
Spero Therapeutics Inc (SPRO) 最新ニュース
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges - Investing.com
Spero Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN
Spero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Spero Therapeutics faces Nasdaq delisting over share price - Investing.com India
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire
UPDATESpero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Marjorie Taylor Greene Is Betting Big on Palantir Stock. Should You? - The Globe and Mail
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Rare Disease Biotech Spero Therapeutics Takes Stage at Major TD Cowen Healthcare Conference - StockTitan
Can Spero Therapeutics' Rare Disease Pipeline Impress Investors at Major Healthcare Conference? - StockTitan
Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN
Spero therapeutics CFO sells $16,137 in stock By Investing.com - Investing.com Nigeria
Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News
Spero therapeutics director Ankit Mahadevia sells $53,990 in stock By Investing.com - Investing.com Australia
Spero Therapeutics CEO sells shares worth $121,159 - MSN
Spero therapeutics CFO sells $16,137 in stock - Investing.com India
Spero therapeutics director Ankit Mahadevia sells $53,990 in stock - MSN
Spero Therapeutics Inc (SPRO) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
An Analysis of Spero Therapeutics Inc (SPRO)’s Potential Price Growth - Knox Daily
Stock Market Recap: Spero Therapeutics Inc (SPRO) Concludes at 0.75, a -6.19 Surge/Decline - The Dwinnex
Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough - Simply Wall St
Spero Therapeutics’ (SPRO) Buy Rating Reiterated at HC Wainwright - Defense World
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts - Benzinga
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know - MSN
Spero Therapeutics stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Spero Therapeutics stock hits 52-week low at $0.92 - Investing.com India
TD Cowen Downgrades Spero Therapeutics (SPRO) - MSN
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin? - Marketscreener.com
Geode Capital Management LLC Decreases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Discloses Financial Estimates and Leadership Changes Amid SEC InvestigationOn January 7, 2025, Spero Therapeutics, Inc. (NASDAQ: SPRO) released a significant update and disclosed estimated financial information as of December 3 - Defense World
Spero Therapeutics, Inc. Announces CEO Changes - Marketscreener.com
Spero Therapeutics announces interim leadership amid SEC inquiry - Investing.com India
Spero Therapeutics announces interim leadership changes - TipRanks
Spero Therapeutics Inc (SPRO) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.55%
大文字化:
|
ボリューム (24 時間):